兆科眼科-B(06622.HK)就TAB014藥物營銷許可等與東曜藥業訂立補充協議
格隆匯3月9日丨兆科眼科-B(06622.HK)發佈公吿,公司全資附屬公司兆科廣州與東曜藥業(1875.HK)的全資附屬公司蘇州東曜訂立一份補充協議,據此,兆科廣州將對執行TAB014的臨牀試驗擁有全面控制權及責任,並對TAB014的開發及在中國大陸,中國香港、中國澳門商業化擁有最終決策權。兆科廣州亦獲得就新生血管濕性老年黃斑部病變以外其他眼科適應症開發TAB014或就眼科適應症開發創新藥方的權利。蘇州東曜將繼續負責生產TAB014作臨牀試驗及商業用途。
根據現行補充協議,由於對合作模式作出調整,故商業化里程碑付款的付款時間表亦已相應調整,致使時間表主要與TAB014的監管審批進度掛鈎,而總里程碑付款額與原協議所列者一致。董事會認為,訂立現行補充協議旨在進一步精簡TAB014的開發及商業化工作,並提高TAB014在商業上成功的機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.